

Request for Prior Authorization

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

ANTIDEPRESSANTS

(PLEASE PRINT - ACCURACY IS

Patient address				
Provider NPI Prescriber name			Phone	
Prescriber address			Fax	
Pharmacy name Address			Phone	
Prescriber must complete all information above. It must be leg	jible, correct, and co	omplete or fo	orm will be returr	ned.
Pharmacy NPI Pharmacy fax		NDC 		
 Documentation of a previous trial and therapy failure and 4) Documentation of a previous trial and therapy fai generic antidepressant; and 5) Documentation of a prev vilazodone; and 6) Documentation of a previous trial and 	lure at a therapeu ious trial and ther d therapy failure a	tic dose wi apy failure t a therape	th one non-SSF at a therapeuti utic dose with	RI/SNRI c dose wit vortioxetin
adjunct; and 8) If the request is for dextromethorphan a the trials must include a previous trial and inadequate re bupropion agent; and 9) If the request is for an isomer, p of the trials must be with the preferred parent drug of th with a documented intolerance. The required trials may that the use of these agents would be medically contrain	nd bupropion extendesponse at a thera prodrug or metabo e same chemical be overridden wh	ended- relea speutic dos plite of the entity that i	ase tablet (Auvo e with an exten requested med resulted in a pa	elity), one ided-releas ication, on irtial respo
and 7) Documentation of a previous trial and therapy fai adjunct; and 8) If the request is for dextromethorphan a the trials must include a previous trial and inadequate rebupropion agent; and 9) If the request is for an isomer, pof the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred	nd bupropion extendesponse at a thera prodrug or metabo e same chemical be overridden who ndicated.	ended- relea speutic dos plite of the entity that r en docume	ase tablet (Auvo e with an exten requested med resulted in a pa	elity), one ided-releas ication, on irtial respo
adjunct; and 8) If the request is for dextromethorphan a the trials must include a previous trial and inadequate rebupropion agent; and 9) If the request is for an isomer, pof the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred Auvelity Fetzima Other:	nd bupropion extension extensions at a there or or metabore same chemical of the overridden who dicated.	ended- relea opeutic dos plite of the entity that rended	ase tablet (Auvo e with an exten requested med resulted in a pa nted evidence	elity), one ided-releas ication, on irtial respo
adjunct; and 8) If the request is for dextromethorphan a the trials must include a previous trial and inadequate re bupropion agent; and 9) If the request is for an isomer, pof the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred Auvelity Fetzima Other:	nd bupropion extension extensions at a there or or metabore same chemical of the overridden who dicated.	ended- relea opeutic dos plite of the entity that rended	ase tablet (Auvo e with an exten requested med resulted in a pa nted evidence	elity), one ided-releas ication, on irtial respo
adjunct; and 8) If the request is for dextromethorphan at the trials must include a previous trial and inadequate rebupropion agent; and 9) If the request is for an isomer, pof the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred Auvelity Fetzima Other: Strength Dosage Instructions Diagnosis: Preferred Generic SSRI Trial 1: Drug Name & Dose	nd bupropion exters esponse at a there esponse	ended- relea speutic dos plite of the entity that rendocume	ase tablet (Auve e with an exten requested med resulted in a pa nted evidence Supply	elity), one ided-releas ication, on irtial respo is provided
adjunct; and 8) If the request is for dextromethorphan at the trials must include a previous trial and inadequate rebupropion agent; and 9) If the request is for an isomer, por the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred Auvelity Fetzima Other: Dosage Instructions Diagnosis: Preferred Generic SSRI Trial 1: Drug Name & Dose Failure Reason	nd bupropion extension extensions at a there or or metabore same chemical observation when dicated. Quantity	ended- relea opeutic dos olite of the entity that i en docume	ase tablet (Auve e with an exten requested med resulted in a pa nted evidence	elity), one ided-releas ication, on irtial respo is provided
adjunct; and 8) If the request is for dextromethorphan as the trials must include a previous trial and inadequate resource of the trials must be with the preferred parent drug of the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred Auvelity Fetzima Other: Dosage Instructions Diagnosis: Preferred Generic SSRI Trial 1: Drug Name & Dose Failure Reason Preferred Generic SSRI Trial 2: Drug Name & Dose	nd bupropion extersions at a there exponse at a there or metabore same chemical be overridden who dicated. Quantity	ended- relea apeutic dos plite of the entity that rendocume Days S	ase tablet (Auve e with an exten requested med resulted in a pa nted evidence Supply _Trial Dates:	elity), one ided-releas ication, on irtial respo is provided
adjunct; and 8) If the request is for dextromethorphan as the trials must include a previous trial and inadequate rebupropion agent; and 9) If the request is for an isomer, por the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred Auvelity Fetzima Other: Dosage Instructions Diagnosis: Preferred Generic SSRI Trial 1: Drug Name & Dose Failure Reason Preferred Generic SSRI Trial 2: Drug Name & Dose Failure Reason Preferred Generic SNRI Trial: Drug Name & Dose Failure Reason	nd bupropion extension extensions at a thera prodrug or metable e same chemical de overridden who dicated. Quantity	ended- relea apeutic dos blite of the entity that rendocume Days S	ase tablet (Auvere with an extended extended in a particular of the control of th	elity), one ided-releas ication, or irtial respo is provided
adjunct; and 8) If the request is for dextromethorphan at the trials must include a previous trial and inadequate rebupropion agent; and 9) If the request is for an isomer, pof the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred Auvelity Fetzima Other: Dosage Instructions Diagnosis: Preferred Generic SSRI Trial 1: Drug Name & Dose Failure Reason Preferred Generic SSRI Trial 2: Drug Name & Dose Failure Reason Preferred Generic SNRI Trial: Drug Name & Dose Preferred Generic SNRI Trial: Drug Name & Dose	nd bupropion extension extensions at a thera prodrug or metable e same chemical de overridden who dicated. Quantity	ended- relea apeutic dos blite of the entity that rendocume Days S	ase tablet (Auvere with an extended extended in a particular of the control of th	elity), one ided-releas ication, on irtial respo is provided
adjunct; and 8) If the request is for dextromethorphan at the trials must include a previous trial and inadequate rebupropion agent; and 9) If the request is for an isomer, pof the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contraint. Non-Preferred	nd bupropion extension of the extension	ended- release peutic dos plite of the entity that rendocume	ase tablet (Auvere with an extended requested med resulted in a particle evidence supply Trial Dates: Trial Dates:	elity), one ided-releas ication, on irtial respo is provided
adjunct; and 8) If the request is for dextromethorphan a the trials must include a previous trial and inadequate rebupropion agent; and 9) If the request is for an isomer, pof the trials must be with the preferred parent drug of the with a documented intolerance. The required trials may that the use of these agents would be medically contrain Non-Preferred Auvelity Fetzima Other:	nd bupropion extersions at a theraproper at a theraprodrug or metabore same chemical be overridden who indicated. Quantity Drug Name & Dose	ended- release peutic dos plite of the entity that rendocume	ase tablet (Auve e with an exten requested med resulted in a painted evidence SupplyTrial Dates: Trial Dates:	elity), one ided-releas ication, or irtial respo is provided



Request for Prior Authorization

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

Date of submission

ANTIDEPRESSANTS (PLEASE PRINT – ACCURACY IS

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary, by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)